Incyte Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Did you know?
Holds 89.3x more cash than debt — a strong balance sheet.
Current Price
$96.91
+1.72%GoodMoat Value
$271.40
180.1% undervaluedProfile
Valuation (TTM)
Market Cap$19.29B
P/E13.47
EV$14.21B
P/B3.73
Shares Out199.01M
P/Sales3.60
Revenue$5.36B
EV/EBITDA8.18
Incyte Corp (INCY) Stock News
INCY Stock News & Headlines
Latest stock news and headlines for Incyte Corp (INCY). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $96.91. Market cap: $19.29B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to INCY from financial news sources, helping investors stay current on events that may impact Incyte Corp's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Incyte Corp (INCY).